Key Highlights

Risk & Performance

Pipeline Risk Assessment

Pipeline Risk Assessment

Based on historical performance

High Risk

Score: 80/100

Failure Rate

36.4%

4 terminated/withdrawn out of 11 trials

Success Rate

63.6%

-22.9% vs industry average

Late-Stage Pipeline

0%

0 trials in Phase 3/4

Results Transparency

57%

4 of 7 completed trials have results

Key Signals

4 with results

Enrollment Performance

Analytics

Phase 1
8(72.7%)
Phase 2
3(27.3%)
11Total
Phase 1(8)
Phase 2(3)

Activity Timeline

Global Presence

Loading network data...

Clinical Trials (11)

Showing 11 of 11 trials
NCT03654755Phase 2Terminated

Study to Evaluate Long-Term Safety of ASN002 in Subjects With Moderate to Severe Atopic Dermatitis

Role: lead

NCT03531957Phase 2Completed

Phase 2B Study to Evaluate ASN002 in Subjects With Moderate to Severe Atopic Dermatitis (RADIANT)

Role: lead

NCT02440685Phase 1Terminated

A Phase 1/2 Study To Evaluate ASN002 In Relapsed/Refractory Lymphoma And Advanced Solid Tumors

Role: lead

NCT03139981Phase 1Completed

A Study To Evaluate ASN002 In Subjects With Atopic Dermatitis

Role: lead

NCT03798561Phase 1Completed

Study to Evaluate ASN008 Topical Gel (TG)

Role: lead

NCT02961283Phase 1Terminated

Study of ASN003 in Subjects With Advanced Solid Tumors

Role: lead

NCT03728504Phase 2Completed

Study to Evaluate ASN002 in Subjects With Moderate To Severe Chronic Hand Eczema

Role: lead

NCT02853643Phase 1Completed

Single Ascending Dose Study to Evaluate Pharmacokinetics and Food-Effect in Healthy Volunteers

Role: lead

NCT03415126Phase 1Completed

A Study of ASN007 in Patients With Advanced Solid Tumors

Role: lead

NCT03641573Phase 1Completed

Phase 1 Study to Evaluate ASN002 Absorption, Metabolism, and Excretion of [14C] Following a Single Oral Dose in Healthy Male Subjects

Role: lead

NCT02349139Phase 1Terminated

Safety, Preliminary Efficacy and Pharmacokinetics of ASN001 in Metastatic Castrate Resistant Prostate Cancer

Role: lead

All 11 trials loaded